Large-scale pharmacoepidemiological research on treatment resistance relies on accurate identification of people with treatment-resistant schizophrenia (TRS) based on data that are retrievable from administrative registers. This is usually approached by operationalising clinical treatment guidelines by using prescription and hospital admission information. We examined the accuracy of an algorithm-based definition of TRS based on clozapine prescription and/or meeting algorithm-based eligibility criteria for clozapine against a gold standard definition using case notes. We additionally validated a definition entirely based on clozapine prescription. 139 schizophrenia patients aged 18-65years were followed for a mean of 5years after first pres...
Treatment-resistant schizophrenia (TRS) will affect about one in three patients with schizophrenia. ...
Around a quarter of people who experience a first episode of psychosis (FEP) will develop treatment-...
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antips...
Large-scale pharmacoepidemiological research on treatment resistance relies on accurate identificati...
© Copyright 2019 Physicians Postgraduate Press, Inc. Treatment-resistant schizophrenia (TRS) occurs ...
BACKGROUND: Clozapine remains the only evidence-based antipsychotic for treatment-resistant schizoph...
OBJECTIVE: Research and clinical translation in schizophrenia is limited by inconsistent definitions...
Treatment-resistant schizophrenia, also known as refractory schizophrenia, is a severe and debilitat...
BACKGROUND: Clozapine remains the only evidence-based antipsychotic for treatment-resistant schizoph...
Objective: Research and clinical translation in schizophrenia is limited by inconsistent definitions...
Although approximately 1/3 of individuals with schizophrenia are Treatment Resistant (TR), identifyi...
Treatment-resistant schizophrenia (TRS) is most defined as an inadequate response in schizophrenia s...
Despite pharmacological advances in the treatment of schizophrenia, significant number of patients c...
ABSTRACT: Purpose: To discuss the importance of 1). Closely monitoring antipsychotic treatment and 2...
Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associate...
Treatment-resistant schizophrenia (TRS) will affect about one in three patients with schizophrenia. ...
Around a quarter of people who experience a first episode of psychosis (FEP) will develop treatment-...
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antips...
Large-scale pharmacoepidemiological research on treatment resistance relies on accurate identificati...
© Copyright 2019 Physicians Postgraduate Press, Inc. Treatment-resistant schizophrenia (TRS) occurs ...
BACKGROUND: Clozapine remains the only evidence-based antipsychotic for treatment-resistant schizoph...
OBJECTIVE: Research and clinical translation in schizophrenia is limited by inconsistent definitions...
Treatment-resistant schizophrenia, also known as refractory schizophrenia, is a severe and debilitat...
BACKGROUND: Clozapine remains the only evidence-based antipsychotic for treatment-resistant schizoph...
Objective: Research and clinical translation in schizophrenia is limited by inconsistent definitions...
Although approximately 1/3 of individuals with schizophrenia are Treatment Resistant (TR), identifyi...
Treatment-resistant schizophrenia (TRS) is most defined as an inadequate response in schizophrenia s...
Despite pharmacological advances in the treatment of schizophrenia, significant number of patients c...
ABSTRACT: Purpose: To discuss the importance of 1). Closely monitoring antipsychotic treatment and 2...
Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associate...
Treatment-resistant schizophrenia (TRS) will affect about one in three patients with schizophrenia. ...
Around a quarter of people who experience a first episode of psychosis (FEP) will develop treatment-...
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antips...